New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:45 EDTSRPTLeerink still cautious on FDA approving eteplirsen with existing data
Leerink says it continues to have reservations that the FDA will approve Sarepta's eteplirsen on its existing data set. The firm thinks today's news supports its belief that the FDA is "kicking the can down the road" on an eteplirsen decision until it obtains more analyzed data. Leerink reiterates a Market Perform rating on Sarepta with a $31 price target.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:15 EDTSRPTSarepta reports Q4 adjusted EPS (94c), consensus (82c)
Subscribe for More Information
February 17, 2015
17:14 EDTSRPTPoint72 lowers passive stake in Sarepta to 4.4% from 5.2%
Subscribe for More Information
12:50 EDTSRPTOn The Fly: Midday Wrap
Subscribe for More Information
10:00 EDTSRPTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTSRPTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Vipshop Holdings (VIPS), up 10.9%... VASCO Data Security (VDSI), up 7.1%... Waste Management (WM), up 3.7%. ALSO HIGHER: Starwood Hotels (HOT), up 1.9% after appointing Adam Aron as interim CEO... Sarepta Therapeutics (SRPT), up 7.3% after being upgraded at BofA/Merrill... Navidea Biopharmaceuticals (NAVB), up 7.5% after publishing results of phase 3 Lymphoseek trial... Campus Crest (CCG), up 7.7% after announcing that it will explore strategic alternatives as well as Clinton Group and Campus Evolution proxy contest... Cyren (CYRN), up 7.1% following distribution agreement with ALSO Deutschland. DOWN AFTER EARNINGS: Helix Energy (HLX), down 13.3%... Walter Energy (WLT), down 10.1%. ALSO LOWER: Celsus Therapeutics (CLTX), down 82.3% after MRX-6 Cream 2% Phase II trial did not meet primary endpoint... Vascular Biogenics (VBLT), down 53.2% after reporting that VB-201 Phase 2 studies did not meet primary endpoints and removal of FDA partial clinical hold on VB-111... Vanguard Natural Resources (VNR), down 7.1% after reporting preliminary fourth quarter results.
07:43 EDTSRPTSarepta upgraded at BofA/Merrill
As previously reported, BofA/Merrill upgraded Sarepta to Buy from Neutral. The firm has increased confidence that eleplirsen will be approved for treating boys with DMD. Price target raised to $21 from $19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use